Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.

PURPOSE: Large data-based studies have reported excess cardiovascular mortality in high-risk patients treated with azithromycin, but whether or not azithromycin causes QT prolongation remains controversial. The purpose of this study was to examine the association of azithromycin treatment on QT prolongation in a cohort of patients hospitalized with community-acquired pneumonia (CAP) METHODS: One-hundred twenty-two hospitalized patients with CAP were enrolled in the study. We compared the baseline QTc, with daily post antibiotic QTc. Other risk factors for QT prolongation such as medication or electrolyte abnormalities were recorded. RESULTS: Ninety (73.8%) patients were treated with azithromycin (usually in combination with ceftriaxone), and 32 (26.2%) patients with other antibiotics (ampicillin-clavulanate, chloramphenicol, doxcycline, or ceftriaxone); 72.1% (88) of the cohort experienced QT lengthening; 72.7% with QT lengthening had a normal baseline QTc. Azithromycin was not associated with the post-antibiotic QTc. Wide (pathological) post-antibiotic QTc was associated with the pneumonia score. Every 10-point increase in the pneumonia score raised the risk for a pathological post antibiotic QTc by 1.249 (95%CI: 1.050-1.486). Analysis of patients with non-pathological baseline QTc revealed that pathological post-antibiotic QTc was only associated with previous stroke and not with the type of antibiotic. CONCLUSIONS: Azithromycin treatment was not associated with QT prolongation in patients with severe CAP. Nonetheless, in a large majority of hospitalized CAP patients, QT prolongation and pathological QTc develop regardless of the antibiotic used, especially in patients with previous stroke or a higher pneumonia score.

Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding.

Low/medium-bleeding-risk populations undergoing percutaneous coronary intervention (PCI) show significantly less bleeding with bivalirudin (BIV) than with unfractionated heparin (UFH), but this has not been established for high-risk patients. We performed a randomized double-blind prospective trial comparing efficacy and safety of BIV versus UFH combined with dual antiplatelet therapy during PCI among 100 high-risk patients with non-ST elevation myocardial infarction (NSTEMI) or angina pectoris. The baseline characteristics were similar in both treatment arms. A radial approach was used in 84% of patients with a higher rate in the BIV group (90 vs. 78%, p < 0.05). Study end points were: major and minor bleeding, port-of-entry complications, major adverse cardiac events (MACE) in-hospital, and at long-term follow-up. There was one case of major gastrointestinal bleeding in the BIV group and 7% minor bleeding complications in both categories. Rate of periprocedural myocardial infarction (PPMI) in the BIV group was twice that in the UFH group (20 vs. 10%, p < 0.16). In-hospital MACE rate was higher in BIV patients as well (12 vs. 2%, p = 0.1). By univariate analysis, the femoral approach was the predictor of PPMI and in-hospital MACE. In a multivariate model, the independent predictor of PPMI was previous MI (odds ratio, 7.7; p < 0.0158). PPMI was 49.7 times more likely with the femoral approach plus BIV than the nonfemoral approach plus UFH (p < 0.0021). At 41.5 ± 14 months' follow-up, end points did not significantly differ between the groups. In patients at high risk for bleeding undergoing PCI, BIV was not superior to UFH for bleeding complications, and early and late clinical outcomes.

Implantation of a resynchronization implantable cardioverter defibrillator in a patient with persistent left superior vena cava.

Implantation of resynchronization implantable cardioverter defibrillator was performed in a patient with persistent left superior vena cava. A dual coil defibrillation lead was inserted in the right ventricle apex via a small innominate vein. Left ventricular and atrial leads were implanted through persistent left superior vena cava. Left ventricular lead was easily implanted into the postero lateral vein. Pacing thresholds and sensing values were excellent and remained stable at 18 months follow-up.Presence of persistent left superior vena cava generally makes transvenous lead implantation difficult. However when a favorable coronary sinus anatomy is also present, it may facilitate left ventricular lead positioning in the coronary sinus branches.

[Biphasic versus monophasic shock waveforms for transthoracic cardioversion of atrial flutter in the emergency room].

UNLABELLED: Transthoracic electrical cardioversion (ECV), traditionally using monophasic waveform (MW) shock, has an important role in the treatment of symptomatic atrial flutter (AFI). Biphasic waveform (BW) shock has been demonstrated to be more successful than MW shock for termination of atrial fibrillation, but data about its use for ECV of AFI are limited. METHODS AND RESULTS: We retrospectively analyzed the records of 53 patients (pts) admitted -to the ER due to symptomatic AFl during the period August 2004 to August 2005: 31 pts received BW shock and 22 pts MW shock. The type of shock waveforms and the initial energy of CV were chosen by the doctor on duty in the ER; the lower energy for ECV was 20 joules, which was increased to 50, 100 and 200 joules if necessary. There were no significant differences between the clinical characteristics of the pts who received BW shock or MW shock. All pts underwent ECV via anterior-laterally positioned hand-held electrode paddles. Successful ECV by BW shock and MW shock was 41% and 42% of the pts, respectively, using 20 joules of energy (p=n.s.); 77% and 80% using 50 joules (p=n.s.); 93% and 90% using 100 joules (p = n.s.); 100% of successful ECV was reached when 200 joules of energy was used, regardless of waveforms type. Median energy for successful ECV was 50 joules in both types of electrical waveforms. No complications were reported. CONCLUSIONS: There were no significant differences in the success rates of conversion of atrial flutter to sinus rhythm by BW or MW shock. We recommend 50 joules for starting energy of ECV of AF1 regardless of waveforms type.

Endocardial ventricular pacing through a bioprosthetic tricuspid valve.

A patient with bioprosthetic tricuspid valve was treated with ventricular endocardial pacing using a new delivery system consisting of a steerable catheter and a 4.1 F bipolar, fixed-screw, steroid eluting lead. The functioning of the lead and bioprosthetic tricuspid valve was excellent during the following year.

[Biphasic shock waveform for cardioversion of atrial fibrillation in the emergency room].

UNLABELLED: Transthoracic electrical cardioversion, traditionally monophasic shock waveform, has been a mainstay of the therapy for atrial fibrillation (AF) since its introduction into clinical practice. Recent studies have demonstrated that biphasic shock is more efficient than monophasic shock waveforms for terminating both ventricular fibrillation and AF; however, data on the recommended initial shock energy in conversion of AF by biphasic shocks are limited. AIM: Our study aimed to evaluate the optimal dose of the initial shock energy for conversion of AF to sinus rhythm by transthoracic biphasic shock waveforms in the Emergency Room (ER). METHODS AND RESULTS: A total of 144 consecutive patients, who came to the ER because of AF, were our study population. All patients underwent cardioversion via anterior-laterally positioned hand-held electrode paddles. Patients received sequential shocks of 50 J (only the first 40 patients), 100 J, 150 J and 200 J if necessary. There was a significantly greater cumulative conversion success rate with 100 J (70.5%) than 50 J shock energy (55%), p < 0.05; but even greater with 150 J (89%) than 100 J shock energy, p < 0.003; no significant difference was observed between 200 J (94%) and 150 J shock energy, p < 0.58. Nine of 12 patients, whose body weight was less than 70 kg, were successfully converted to sinus rhythm (75%) by 50 J shock 1 energy. After cardioversion there were reports of: a five seconds asystole observed in 1 patient; pulmonary edema in another patient; hypotension was reported in 1 patient and mild erythema in 14 patients (9.7%). CONCLUSION: Our findings support that biphasic waveform shock energy of 150 J is advised as a first attempt, but in patients with a body weight less than 70 kg. lower energy shock may be used.

Unsuccessful rescrewing of a dislodged screw-in atrial lead.

We report a case of unsuccessful rescrewing of an atrial lead after its early dislodgment in a 64 years old patient because of entrapped endocardial tissue in the screw-in system.

Incidence of postdischarge symptomatic paroxysmal atrial fibrillation in patients who underwent coronary artery bypass graft: long-term follow-up.

The aim of this retrospective study was to determine the incidence of symptomatic AF of patients who had undergone coronary artery bypass grafting (CABG) during long-term follow-up. The study population included 305 post-CABG patients who were regularly followed in the outpatient clinic. Paroxysmal AF (PAF) was defined as an episode of symptomatic AF when symptoms were prolonged enough for the patient to request medical care. Perioperative AF occurred in 88 (28.9%) patients. Postdischarge symptomatic PAF occurred in 25 (8.2%) patients with an annual incidence of 2% during a mean follow-up of 48 +/- 30 months. Eighteen (20.4%) patients also experienced perioperative AF with an annual incidence of 5.1%, while only 7 (3.2%) of 217 patients, without perioperative AF, had postdischarge AF (P < 0.0003). During long-term follow-up, postdischarge AF has a low incidence and prophylactic antiarrhythmic therapy is not recommended. The method of follow-up and retrospective analysis may understate PAF and even miss some symptomatic episodes. Perioperative AF is a predictor of symptomatic late PAF recurrences, particularly in patients with reduced left ventricular function.